Improved heart repair upon myocardial infarction: Combination of magnetic nanoparticles and tailored magnets strongly increases engraftment of myocytes

Ottersbach, Annika; Mykhaylyk, Olga; Heidsieck, Alexandra; Eberbeck, Dietmar; Rieck, Sarah; Zimmermann, Katrin; Breitbach, Martin; Engelbrecht, Britta; Brügmann, Tobias; Hesse, Michael; Welz, Armin; Sasse, Philipp; Wenzel, Daniela; Plank, Christian; Gleich, Bernhard; Hölzel, Michael; Bloch, Wilhelm; Pfeifer, Alexander; Fleischmann, Bernd K.; Roell, Wilhelm

doi:10.1016/j.biomaterials.2017.11.012

Cited by 55 publications

(57 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of the subcellular localization of MNPs showed that, unlike macrophages, mesenchymal or tumor cells, which are able to internalize different types of MNPs [56,70,[108][109][110], lymphoid cells are apparently unable to do so ( Figure 3) [78,79,111,112]. It is widely described that the uptake of NPs depends on the cell type [113,114].…”

Section: The Interaction Between Mnps and Lymphoid Cellsmentioning

confidence: 99%

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

2020

View full text Add to dashboard Cite

Adoptive cell transfer therapy is a promising anti-tumor immunotherapy in which effector immune cells are transferred to patients to treat tumors. However, one of its main limitations is the inefficient trafficking of inoculated effector cells to the tumor site and the small percentage of effector cells that remain activated when reaching the tumor. Multiple strategies have been attempted to improve the entry of effector cells into the tumor environment, often based on tumor types. It would be, however, interesting to develop a more general approach, to improve and facilitate the migration of specific activated effector lymphoid cells to any tumor type. We and others have recently demonstrated the potential for adoptive cell transfer therapy of the combined use of magnetic nanoparticle-loaded lymphoid effector cells together with the application of an external magnetic field to promote the accumulation and retention of lymphoid cells in specific body locations. The aim of this review is to summarize and highlight the recent findings in the field of magnetic accumulation and retention of effector cells in tumors after adoptive transfer, and to discuss the possibility of using this approach for tumor targeting with chimeric antigen receptor (CAR) T-cells.

show abstract

Section: The Interaction Between Mnps and Lymphoid Cellsmentioning

confidence: 99%

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

2020

View full text Add to dashboard Cite

show abstract

“…Even though the expression pattern was inhomogeneous, VT-incidence was consistently reduced, confirming our earlier findings that engraftment of low numbers of Cx43 expressing cells suffices to strongly reduce electrical vulnerability 14 . In future studies multiple virus injections into the scar area and/or the combination of nanoparticles with magnets could be probed to further increase transduction efficiency of resident cells and potentially also the anti-VT effect 36 . Direct lentivirus delivery did not affect cardiac function and remodeling, as basic ECG- and morphometric parameters were unchanged following injection; accordingly, we could not find lentivirus transduction of non-infarcted heart tissue.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of Cx43 in cells of the myocardial scar: Correction of post-infarct arrhythmias through heterotypic cell-cell coupling

Roell

Klein

Breitbach

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

Ventricular tachycardia (VT) is the most common and potentially lethal complication following myocardial infarction (MI). Biological correction of the conduction inhomogeneity that underlies re-entry could be a major advance in infarction therapy. As minimal increases in conduction of infarcted tissue markedly influence VT susceptibility, we reasoned that enhanced propagation of the electrical signal between non-excitable cells within a resolving infarct might comprise a simple means to decrease post-infarction arrhythmia risk. We therefore tested lentivirus-mediated delivery of the gap-junction protein Connexin 43 (Cx43) into acute myocardial lesions. Cx43 was expressed in (myo)fibroblasts and CD45+ cells within the scar and provided prominent and long lasting arrhythmia protection in vivo. Optical mapping of Cx43 injected hearts revealed enhanced conduction velocity within the scar, indicating Cx43-mediated electrical coupling between myocytes and (myo)fibroblasts. Thus, Cx43 gene therapy, by direct in vivo transduction of non-cardiomyocytes, comprises a simple and clinically applicable biological therapy that markedly reduces post-infarction VT.

show abstract

“…Magnetoliposomes (MLs) are composed of liposomes and magnetic NPs and are the first efficient hybrid liposome/NP systems produced for the drug delivery ( Namdari et al, 2017 ). In this line, several experimental strategies have been investigated the potential scope of magnetic NPs to leverage the delivery of growth factors, cytokines, and biomolecules to the degenerating cardiac cells and tissues and enhance their regeneration ( Allen and Cullis, 2013 ; Paul et al, 2014 ; Ottersbach et al, 2018 ).…”

Section: Organic-inorganic Hybrid Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Fan

Joshi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.

show abstract

Improved heart repair upon myocardial infarction: Combination of magnetic nanoparticles and tailored magnets strongly increases engraftment of myocytes

Cited by 55 publications

References 47 publications

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting

Overexpression of Cx43 in cells of the myocardial scar: Correction of post-infarct arrhythmias through heterotypic cell-cell coupling

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Contact Info

Product

Resources

About